ORD_61355/2024 | EP4026488 | UPC Decision Search

	Type Order Decision	Reference	Court Division Brüssel Brussels Copenhagen Den Haag Düsseldorf Hamburg Helsinki Lisbon Lissabon Luxembourg Luxemburg Mailand Mannheim Milan München Munich Nordic Baltic Regional Division Paris The Hague Vienna			Tags
20 November, 2024	Order	ORD_61355/2024	Düsseldorf (DE) Loca…	EP4026488	R. 9.3 (a) RoP ...	Please log in to add tags.	Please log in to add notes. Please log in to add tags. Show on UPC ORD_61355/2024 20 November, 2024 Order Summary (AI generated) Party DexCom, Inc. Registry Information Registry Number: App_60996/2024 Court Division: Düsseldorf (DE) Local Division Type of Action: Generic application Language of Proceedings: EN Patent at issue EP4026488 Sections Keywords (EN) R. 9.3 RoP, Extension of time limits, fairness and equity Cited Legal Standards R. 29(e) RoP R. 32.3 clause 1 RoP R. 9.3 (a) RoP R. 9 RoP Documents Download Order (EN) Add a custom note or summary to this decision Styles Text Heading 1 Heading 2 Heading 3 Bold ⌘B Italic ⌘I Strikethrough ⌘+Shift+S Bullet list Ordered list Blockquote ⌘+Shift+B Insert link ⌘K Insert link Unlink Align Left Center Right Düsseldorf Local Division UPC_CFI_499/2023 Procedural Order of the Court of First Instance of the Unified Patent Court issued on 20 November 2024 concerning EP 4 026 488 CLAIMANT: DexCom, Inc., 6340 Sequence Drive, San Diego, California represented by its CEO Kevin Sayer, represented by: Dr. Markus Grosch, Dr. Johannes Bukow, Dr. Jan Axtmann, Paul Lehmann, Quinn Emanuel Urquhart & Sullivan LLP, Mollstraße 42, 68165 Mannheim, Germany, electronic address for service: marcusgrosch@quinnemanuel.com DEFENDANTS: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6400, USA, represented by its board of directors which is represented by the CEO Robert Ford, Abbott Diabetes Care Inc., 1360 South Loop Road, Ala-meda, California 94502, USA, represented by its president Jared Watkin, Abbott GmbH, Max-Planck-Ring 2, 65205 Wiesbaden, Germany, represented by its managing director Konstantinos Varlas, Abbott Diagnostics GmbH, Max-Planck-Ring 2, 65205 Wiesbaden, Germany, represented by its managing directors Philip Boudreau and Konstantinos Varlas, Abbott Laboratories GmbH, Freundallee 9A, 30173 Han-over, Germany, represented by its managing directors Gregor Benning, Bradley Slater and Frank Weitekämper, Abbott Logistics B.V., Meeuwenlaan 4, 8011BZ Zwolle, The Netherlands, represented by its directors Hendrikus Lueb and Philip Boudreau, Abbott France (S.A.S.) , 40/48 rue d'Arcueil, 94593 Rungis, France, represented by its president Philippe Emery, Abbott s.r.l., Viale Giorgio Ribotta 9, 00144 Rome, Italy, represented by the chairman of its boards of directors Massi-miliano Bindi, Abbott Gesellschaft m.b.H, Perfektastraße 84A, 1230 Vienna, Austria, represented by its directors Martin Hochstöger, Gerhard Wiesinger and Bradley Slater, Abbott B.V., Wegalaan 9, 2132JD Hoofddorp, The Netherlands, represented by its directors Hendrikus Lueb and Bradley Slater, Abbott (S.A./N.V.), Avenue Einstein 14, 1300 Wavre, Belgium, represented by its directors Hendrikus Lueb, Hasna Nadir and Bradley Slater Abbott Scandinavia Aktiebolag , Hemvärnsgatan 9, 171 54 Solna, Sweden, represented by its board of directors which is represented by the chairman of the board Karl Almroth Abbott Oy, Karvaamokuja 2 A, 00380 Helsinki, Finland, represented by its chairman of the board and chief executive officer Karl Almroth all Defendants represented by: Dr. Dietrich Kamlah, Dr. Christian Lederer, Dr. Gisbert Hoha- gen, Taylor Wessing Partnerschaftsgesellschaft mbB, Isartor- platz 8, 80331 München, Germany electronic address for service: d.kamlah@taylorwessing.com PATENT AT ISSUE: European patent n° EP 4 026 488 PANEL/DIVISION: Panel of the Local Division in Düsseldorf DECIDING JUDGES: This order was issued by Presiding Judge Thomas acting as judge-rapporteur. LANGUAGE OF THE PROCEEDINGS: English SUBJECT OF THE PROCEEDINGS: R. 9.3 (a) RoP - Extension of time periods GROUNDS FOR THE ORDER: The Court notes that the Defendants have not consented to the extension of the time limits. However, the requested extension is justified on the grounds of fairness and equity (see the 5 th recital in the Preamble to the Rules of Procedure), since the previous time limit was, with the consent of the Claimant, extended to a similar extent in favour of the Defendants. If the relevant workflows are (still) blocked at the time the pleadings need to be uploaded to the CMS, there is no objection to using the R. 9 RoP workflow. ORDER: At the request of the Claimant, the time limit for filing the Rejoinder to the Counterclaim for revocation according to R. 29(e) RoP (CC_33181/2024) and for filing the Reply to the conditional Application to amend according to R. 32.3 clause 1 RoP (Appl. No. 45165/2024) are extended until 11 December 2024 . DETAILS OF THE ORDER: App_60996/2024 related to the main proceeding ACT_596853/2023 and CC_33181/2024 UPC-Number: UPC_CFI_499/2023 Subject of the Proceedings: Patent infringement action and Counterclaim for revocation Issued in Düsseldorf on 20 November 2024 Presiding Judge Thomas

ORD_61355/2024

Düsseldorf Local Division UPC_CFI_499/2023

Procedural Order

of the Court of First Instance of the Unified Patent Court issued on 20 November 2024 concerning EP 4 026 488

CLAIMANT:

DexCom, Inc., 6340 Sequence Drive, San Diego, California represented by its CEO Kevin Sayer, represented by:

Dr. Markus Grosch, Dr. Johannes Bukow, Dr. Jan Axtmann, Paul Lehmann, Quinn Emanuel Urquhart & Sullivan LLP, Mollstraße 42, 68165 Mannheim, Germany, electronic address for service:

marcusgrosch@quinnemanuel.com

DEFENDANTS:

1. Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6400, USA, represented by its board of directors which is represented by the CEO Robert Ford,
1. Abbott Diabetes Care Inc., 1360 South Loop Road, Ala-meda, California 94502, USA, represented by its president Jared Watkin,
1. Abbott GmbH, Max-Planck-Ring 2, 65205 Wiesbaden, Germany, represented by its managing director Konstantinos Varlas,
1. Abbott Diagnostics GmbH, Max-Planck-Ring 2, 65205 Wiesbaden, Germany, represented by its managing directors Philip Boudreau and Konstantinos Varlas,
1. Abbott Laboratories GmbH, Freundallee 9A, 30173 Han-over, Germany, represented by its managing directors Gregor Benning, Bradley Slater and Frank Weitekämper,
1. Abbott Logistics B.V., Meeuwenlaan 4, 8011BZ Zwolle, The Netherlands, represented by its directors Hendrikus Lueb and Philip Boudreau,
1. Abbott France (S.A.S.) , 40/48 rue d'Arcueil, 94593 Rungis, France, represented by its president Philippe Emery,
1. Abbott s.r.l., Viale Giorgio Ribotta 9, 00144 Rome, Italy, represented by the chairman of its boards of directors Massi-miliano Bindi,
1. Abbott Gesellschaft m.b.H, Perfektastraße 84A, 1230 Vienna, Austria, represented by its directors Martin Hochstöger, Gerhard Wiesinger and Bradley Slater,
1. Abbott B.V., Wegalaan 9, 2132JD Hoofddorp, The Netherlands, represented by its directors Hendrikus Lueb and Bradley Slater,
1. Abbott (S.A./N.V.), Avenue Einstein 14, 1300 Wavre, Belgium, represented by its directors Hendrikus Lueb, Hasna Nadir and Bradley Slater
1. Abbott Scandinavia Aktiebolag , Hemvärnsgatan 9, 171 54 Solna, Sweden, represented by its board of directors which is represented by the chairman of the board Karl Almroth
1. Abbott Oy, Karvaamokuja 2 A, 00380 Helsinki, Finland, represented by its chairman of the board and chief executive officer Karl Almroth

all Defendants represented by:

Dr. Dietrich Kamlah, Dr. Christian Lederer, Dr. Gisbert Hoha- gen, Taylor Wessing Partnerschaftsgesellschaft mbB, Isartor- platz 8, 80331 München, Germany

electronic address for service:

d.kamlah@taylorwessing.com

PATENT AT ISSUE:

European patent n° EP 4 026 488

PANEL/DIVISION:

Panel of the Local Division in Düsseldorf

DECIDING JUDGES:

This order was issued by Presiding Judge Thomas acting as judge-rapporteur.

LANGUAGE OF THE PROCEEDINGS: English

SUBJECT OF THE PROCEEDINGS: R. 9.3 (a) RoP - Extension of time periods

GROUNDS FOR THE ORDER:

The Court notes that the Defendants have not consented to the extension of the time limits. However, the requested extension is justified on the grounds of fairness and equity (see the 5 th recital in the Preamble to the Rules of Procedure), since the previous time limit was, with the consent of the Claimant, extended to a similar extent in favour of the Defendants.

If the relevant workflows are (still) blocked at the time the pleadings need to be uploaded to the CMS, there is no objection to using the R. 9 RoP workflow.

ORDER:

At the request of the Claimant, the time limit for filing the Rejoinder to the Counterclaim for

revocation according to R. 29(e) RoP (CC_33181/2024) and for filing the Reply to the conditional Application to amend according to R. 32.3 clause 1 RoP (Appl. No. 45165/2024) are extended until 11 December 2024 .

DETAILS OF THE ORDER:

App_60996/2024 related to the main proceeding ACT_596853/2023 and CC_33181/2024

UPC-Number:

UPC_CFI_499/2023

Subject of the Proceedings:

Patent infringement action and Counterclaim for revocation

Issued in Düsseldorf on 20 November 2024

Presiding Judge Thomas